Cargando…
P25 EFFECT OF DARATUMUMAB ON STEM CELL YIELDS IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA: REPORT FROM THE MULTIPLE MYELOMA LAZIO GROUP
Autores principales: | Fazio, F., Passucci, M., Lisi, C., Micozzi, J., Fianchi, L., Di Landro, F., Za, T., Gumenyuk, S., Ferraro, S., Anaclerico, B., De Padua, L., Annibali, O., Rago, A., Piciocchi, A., Bongarzoni, V., Cupelli, L., Mengarelli, A., De Stefano, V., Martelli, M., Petrucci, M.T. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10171491/ http://dx.doi.org/10.1097/01.HS9.0000936228.58804.b9 |
Ejemplares similares
-
P971: EFFECT OF DARATUMUMAB ON STEM CELL YIELDS IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA: REPORT FROM THE MULTIPLE MYELOMA LAZIO GROUP.
por: Fazio, Francesca, et al.
Publicado: (2023) -
Daratumumab combined with dexamethasone and lenalidomide or bortezomib in relapsed/refractory multiple myeloma (RRMM) patients: Report from the multiple myeloma GIMEMA Lazio group
por: Fazio, Francesca, et al.
Publicado: (2022) -
Alkaline phosphatase (alp) levels in multiple myeloma and solid cancers with bone lesions: Is there any difference?
por: Annibali, O., et al.
Publicado: (2020) -
Daratumumab for the Treatment of Multiple Myeloma
por: Plesner, Torben, et al.
Publicado: (2018) -
Daratumumab in dialysis-dependent multiple myeloma
por: Jeyaraman, Preethi, et al.
Publicado: (2020)